Join us as we explore the future of Gene Therapy 

Svar Life Science is in a unique position to offer assistance in any Gene Therapy project. We have extensive experience and knowledge within the field of cell-based assays, immunogenicity and potency through our diagnostic and bioanalytical services. With robust technologies and platforms suited for all phases of drug development, we are the ideal partner when venturing into this new and exciting area. We develop products and offer services to address the obstacles and analytical challenges involved in Gene Therapy.

Bringing the benefits of the iLite® technology to Gene Therapy

The Svar iLite® cell-based platform has a long track record of high reproducibility and ease-of-use. Our assay-ready cells provide fast and high-quality, biologically relevant results for a wide range of targets.

Off-the-shelf cell-based reporter gene assays

  • AAV responsive cell lines ideal for detecting antibodies against the viral vector in human serum
  • Robust in vitro assay for the measurement of therapeutic product potency
  • Measuring immunogenicity effects of therapeutic gene treatment (capsid, DNA cargo and protein)

Testing Services

  • Immunogenicity assessments
  • Potency / Batch release testing

Custom Development

We can tailor projects specific to your needs, mechanism of action and target, developing a cell line that is ideally fit for purpose.

We can help you realize the promise of Gene Therapy!

Read more

25 September 2019

Now you can order from us on the go – send you order directly online

We are delighted to announce the launch of our new online product database and integrated product pages on our new website.

With the addition of product specific information, improved menu functionality and an e-commerce option, our current and prospective customers will be able to find useful information about our products and services on our new website. The new product database functionality includes:

  • New product filtering capabilities at the category level
  • Updated product e-commerce functionality - new shopping cart with “send quote” and “place order” option
  • Direct access to product documentation – linking to resource center with additional content

We’ve also introduced a range of new content to the website, including a Knowledge section that hosts our Resource Center that will feature a library of product specific content such as whitepapers, posters and marketing material. Going forward, we plan to add more content and product support material to provide our customers with all of the information they need to evaluate our products and services.

View Product Portfolio

20 September 2019

Dear industry professionals, partners and friends of Svar Life Science, Wieslab and Calpro,

We are pleased to announce our participation at the following globally leading industry exhibitions for the fall of 2019!

Contact sales@svarlifescience.com today to learn more on our innovative, rapid and streamlined solutions for your drug development, clinical diagnosis and gene therapy projects!

Follow us on LinkedIn for updates on our exiting presentations and launches!

 

DSGH Årsmöte (Calpro)
AUGUST 30-31 - NYBORG

Nordic Life Science Days (Wieslab)
BOOTH 8 – SEPTEMBER 10-12 - MALMÖ

EMCHD (Svar Life Science)
European Meeting on Complement in Human Disease 
BOOTH 6 – SEPTEMBER 14-17 - MADRID

BEBPA (Svar Life Science)
BioPharmaceutical Emerging Best Practices Association
SEPTEMBER 25-27 – PRAGUE

Immunogenicity Bioassay Summit (Svar Life Science)
BOOTH 13 – OCTOBER 15-18 - WASHINGTON

Festival of Biologics (Svar Life Science)
BOOTH 61 – OCTOBER 15-17 - BASEL

UEG Week (Calpro)
United European Gastroenterology
BOOTH 24 – OCTOBER 20-23 - BARCELONA

Bioagora (Wieslab)
NOVEMBER 19 – COPENHAGEN

EBF (Wieslab)
European Bioanalysis Forum
NOVEMBER 20-22 - BARCELONA

IBD Nordic Conference (Calpro)
NOVEMBER 28-29 - MALMÖ

Czech and Slovak Gastroenterological Congress (Calpro)
NOVEMBER 27-28 - PRAGUE

 

5-4

 

2 September 2019

During the summer months (June, July, August) Wieslab will be open as usual

Opening hours for Wieslab Diagnostic Services during the Summer of 2019:
Midsummer, June 21st, 2019 – CLOSED

During the summer months (June, July, August) Wieslab will be open as usual, weekdays (Mon-Fri) 08:00-16:00 CEST (GMT+2 hours).

As we will have reduced workforce due to summer vacation (week 26-32), the reporting times during these period may be slightly longer than usual for certain analyses.

If it is very urgent to get a certain result, you are always welcome contact the laboratory staff directly on telephone +46 40 53 76 60.

Emergency testing

Acute testing (neurology) on suspicion of acute autoimmune encephalitis and/or acute paraneoplastic syndromes will be carried out during normal working hours when the laboratory is staffed, i.e. weekdays 08:00-16:00 CEST (GMT+2 hours).

Samples that arrive before 10 am will be analyzed the same day - see request form for more information.

Please call +46 40 53 76 60 to notify that acute samples for neurological symptoms are on the way to the Laboratory.

We wish you a great summer!

Wieslab AB

 

FOR MORE INFORMATION, PLEASE CONTACT:

Diagnostic.services@svarlifescience.com
Lab Manager, Rita Martins Olofsson: 040 - 643 44 12
Key Account Manager, Monica Blixt: 0708 - 86 28 10
Laboratory: 040 - 53 76 60

Click on the links for more information on:
Sampling instructions
Request Forms
Opening hours
Terms & Conditions

19 June 2019

iLite® IL-23 - offering significant benefits compared to conventional IL-23 assays

Targeting of IL-23 or the IL-23 receptor is a potential therapeutic approach for autoimmune diseases including psoriasis, inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis.

IL-23 is a pro-inflammatory cytokine that shares traits with IL-12. Both cytokines contain the p40 subunit which binds to the receptor chain IL-12Rβ1. However, the two cytokines exert distinct non-redundant biological functions. Emerging data demonstrate that IL-23 is a key participant in central regulation of the cellular mechanisms involved in inflammation and therapeutic agents targeting both IL-23 and IL-12 cytokines are currently used to treat psoriasis and psoriatic arthritis. In addition, related agents are in clinical testing for a variety of inflammatory disorders.


The iLite® IL-23 Assay Ready Cells is derived from a highly specific reporter gene cell line that can discriminate on a subunit level between the sometime cross reactive IL-23 and IL-12 and subsequently be used for quantifying IL-23 activity, IL-23 inhibitor activity, e.g. Ustekinumab and the activity of neutralizing antibodies against the latter.

iLite® Cell-Based Assays
Valuable tools during the whole drug development continuum

iLite® cell lines can be developed for any biopharmaceutical target,  and assays for drug potency, i.e. drug activity, and neutralizing antibodies (NAbs) can easily be set-up using the same cell line. The iLite® technology eliminates many of the limitations of conventional cell-based assays as the cells are delivered as assay ready frozen cells, allowing cell-based assays to be carried out without the need for cell culture or the maintenance of cells continuously in the laboratory.

This allows for significant cost reductions and increases the applicability of cell-based assays to routine use as potency or neutralization assays.

For more information about our iLite® Assay Ready Cells - please click here.

3 April 2019

Colony-stimulating factors (CSF:s) activate and cause the cells to proliferate and differentiate into a specific kind of blood cell, usually white blood cells. There are different types of CSF:s and they have unique biological roles, indicating therapeutic benefits for a number of disease treatments ranging from different cancer forms, viral infections, and autoimmune diseases and as a result, many clinical trials targeting colony-stimulating factors are now well on their way.

Colony-stimulating factors (CSF:s) are secreted glycoproteins that bind to receptor proteins on the surfaces of hematopoietic stem cells, thereby activating intracellular signaling pathways that can cause the cells to proliferate and differentiate into a specific kind of blood cell, usually white blood cells. They play a part in the hosts´ response to injury and infection, and although they were originally defined as hematopoietic cell growth factors, CSF:s have been shown to have additional unique biological functions, suggesting that they could be used to target specific conditions. 

There is a great interest in targeting CSF:s in inflammatory and autoimmune disorders, as well as in cancer. Most CSF compounds of today are pharmaceutical analogs of CSF:s, where Filgrastim, a recombinant form of G-CSF, is the most well known. These therapies can be expensive and require cumbersome administration. New CSF analogues are represented primarily by biosimilars where the originator drug has gone off patent.

Click to learn more about the CSF family, their mechanism of actions, role as pharmaceutical targets and how the novel iLite® growth factor targets enable the study and targeting of human growth factor proteins and their receptors. 

Read more

1 March 2019

MALMÖ, Sweden– February 27, 2019

Following on from the successful launch of IL-2 and IL-6, two new interleukin cell lines, Svar Life Science now introduces another new cell line for use in the growth factor segment - iLite® Assay Ready Cells for G-CSF. 

Granulocyte Colony-Stimulating Factor (G-CSF) is a type of growth factor that impacts the treatment and survival of patients and is used after chemotherapy to help white blood cells recover after treatment or before and after a stem cell transplant.

Designed to be highly specific, with simple and quick protocols, the iLite G-CSF Assay Ready Cells offer a large signal to noise ratio, high matrix tolerance and have high reproducibility.

The world market for G-CSFs is growing rapidly and a major force is the development of G-CSF biosimilars - due to the expiry of existing patents there is considerable interest from many companies to enter the marketplace. A number of biosimilar compounds of traditional G-CSF drugs are in clinical development and the iLite® Platform offers cell-based assays that enable the study and targeting of human growth factor proteins and their receptors. With the advantage of a biologically relevant assay system offering functional and quantitative read-outs, the iLite cell-based assay enables broad usage in applications such as functional screening, functional characterization, QC lot release (potency) assays and neutralizing antibody studies.

The assays are designed as Assay Ready Cells, giving you instant access to your assay. These cell-based assays can also be set up by our in-house GLP and GCP compliant laboratory Wieslab, offering bioanalytical services within (PK/PD), immunogenicity (ADA/NAb) and potency.

“We are delighted to announce several new cell lines during 2019 within our key focus areas. These additions to our cell-based portfolio will support extensions of use for already established products and reflect our continuing investment in the iLite cell-based solution platform” says Therese Segerstein, Product Manager Cell-based Solutions.

Learn more about "Colony Stimulating Factors - their unique biological roles and therapeutic benefits" in our blog post.

View Product Launch Update 

27 February 2019

MALMÖ, Sweden,– February 18, 2019

Svar Life Science, today announced the launch new interleukin cell lines adding to the iLite® portfolio of call-based solutions. These two new products are designed to be highly specific, with simple and quick protocols, large signal to noise ratio, high matrix tolerance and have high reproducibility.

”We are strengthening the cell-based interleukin portfolio with the addition of the iLite® IL-2 and IL- 6. These cell lines broaden our offering within interleukin related disease areas, and they nicely complement our other assay solutions already appreciated by pharmaceutical clients” says Therese Segerstein, Product Manager Cell-based Solutions.

Interleukins have shown to have a pivotal role in the mediation of physiological response to infection and as they contribute significantly to the functional changes that accompany a particular disease or disorder, it has become evident that they represent a group of proteins with potential importance as therapeutic targets.

The iLite® Platform offers cell-based assays that enable the study and targeting of human interleukin proteins and their receptors, while addressing these issues. The assays are designed as Assay Ready Cells and the cell-based assays can also be set up by our in-house laboratory Wieslab offering bioanalytical services in compliance with GLP and GCP.

This enables their broad usage in applications such as functional screening, functional characterization, QC lot release (potency) assays and neutralizing antibody studies. 

“We are always ready to assist clients in accelerating their drug discovery and development programs in the most efficient way by supporting with unique reporter gene assays and tailored laboratory service solutions” adds Therese Segerstein.

 

Learn more about "Why are interleukins interesting targets in biological drug compounds" in our blog post.

View Product Launch Update 

18 February 2019

Interleukins have a pivotal role in the mediation of the physiological response to infection, immune response and contribute significantly to the functional changes that accompany a particular disease or a wide range of disorders. They are a group of naturally occurring proteins that mediate communication between cells and therefore have great potential as therapeutic targets. 

Several interleukins have already become successful treatment targets and many more are in early development or in different stages of clinical trials. These therapies are an increasingly important class of drugs in the treatment and management of many diseases and the main message is that interleukin therapeutics is a rapidly growing field with major pharmaceutical impact.

Click to learn more about the function and signaling of interleukins, potential therapeutic applications and the novel iLite® interleukin targets. 

Read more

 

14 February 2019

iLite® FGF21 Responsive Reporter Gene Cell Line With Improved Sensitivity

FGF21 holds promise to become a powerful drug in the treatment of a wide array of chronic human diseases, demonstrating that novel and potentially better medicines are within reach.

Fibroblast growth factor 21 (FGF21) is a hot target within the diabetes and obesity research and drug discovery. Known to function as an endocrine hormone with documented beneficial metabolic effects, FGF21 has been established as a viable, and excellent drug candidate molecule for therapeutic treatment of diabetes and cardiovascular disease associated with obesity.

The iLite® FGF21 Assay Ready Cells are genetically engineered reporter gene cells responsive to FGF21 by specific and proportional expression of Firefly Luciferase. As transmembrane protein β-Klotho has been identified as the necessary co-receptor able to permit FGF21 mediated activation of FGFRs in vitro and promote FGF21 action in vivo, the receptor chain FGFR1c in this new and improved cell line is overexpressed on the surface together with the co-factor β-Klotho which has been genetically optimized to enhance sensitivity.

FGF21 holds promise to eventually become a powerful drug in the treatment of a wide array of chronic human diseases, demonstrating that novel and potentially better medicines are within the reach.

iLite® Cell-Based Assays
Valuable tools during the whole drug development continuum

iLite® cell lines can be developed for any biopharmaceutical target,  and assays for drug potency, i.e. drug activity, and neutralizing antibodies (NAbs) can easily be set-up using the same cell line. The iLite® technology eliminates many of the limitations of conventional cell-based assays as the cells are delivered as assay ready frozen cells, allowing cell-based assays to be carried out without the need for cell culture or the maintenance of cells continuously in the laboratory.

This allows for significant cost reductions and increases the applicability of cell-based assays to routine use as potency or neutralization assays.

For more information about our iLite® Assay Ready Cells - please click here.

6 February 2019

We´re extending our complement portfolio

Our new activity marker, Complement TCC, is an excellent biomarker for complement studies in basic and translational research, clinical evaluation of treatment, safety studies of medical device and drugs.

Activity markers are used to determine whether deficiencies, overactivation or dysregulation in the complement system are causing, or contributing to, a person's disease or condition.

The Svar Complement activity markers give valuable intelligence in several situations where one might suspect that complement activation plays a role in the disorder. The Svar assays for complement activity markers are developed to target the unique neoepitopes only presented at the complement component or complex when activated.

Just like the Svar Complement C4d, launched in 2018, the Complement TCC is a flexible and easy to use enzyme immunoassay with ready to use reagents and short incubation times leading to reduced hands-on-time for the user.

TCC is suitable for all situations where determination of complement activity is wanted. Increased TCC levels can be detected in both acute injury (trauma, sepsis, myocardial infarction) and in chronic inflammation diseases  (SLE, RA, aHUS) and can be used successfully to rule out if a drug is toxic or if an adverse reaction is due to other related issues such as “infusion reactions”.

TCC is also well suited for studies of all medical devices in contact with blood, i.e. biological safety testing and part of the recommended tests for assessing complement activation according to ISO standard 10993-4 for hemocompatibility testing.

TCC is also well suited for studies of all medical devices in contact with blood, i.e. biological safety testing and part of the recommended tests for assessing complement activation according to ISO standard 10993-4 for hemocompatibility testing.

Benefits of Complement TCC:

  • A versatile marker with broad application area
  • Easy to Use for quick assessment
  • Reliable method with proven trackrecord
  • Help accelerate the drug development process
  • Improve patient safety

For more information about our activity markers - TCC and C4d - please click here.

28 January 2019

 

During the end of 2018, we received  of number of requests for new tests of markers and autoantibodies. This has led to updates on our request form. We have also made some updates of test panels due to new research findings and guidelines.

Since some tests have become more common to offer in routine laboratories, we as a specialist laboratory have decided  to remove tests that cannot be regarded as specialist tests any longer or tests have been removed from our portfolio since research has shown that these no longer give any added diagnostic value. 

We have the pleasure to inform about the following new tests and updates in our portfolio:

NEW TESTS & PANELS AND UPDATES:

Autoimmune Diagnostics

Please note that we have changed the order of the panels on the Request Form.

New Complement Activity Marker: C4d – (No. 911)
In several autoimmune diseases (SLE, Systemic sclerosis, ANCA vasculitis), an elevated plasma C4d can be linked to disease activity and kidney-affected flares. Also, in lung cancer, elevated C4d has been shown to be able to differentiate patients with intermediate nodules and in malignant pleural mesothelioma correlate with tumor volume and chemotherapy response. C4d is a specific biomarker for activity in the complementary system's classic pathway and lectin pathway.

New Panel for Extended Analysis for Suspected Anti-Phospholipid Syndrome (Panel 579)
Anti-Cardiolipin (IgA) No. 017, Anti-Beta-2 Glycoprotein (IgA) No. 146 & Anti-Phosphatidylserine (IgGAM) No. 403 (screening).

New Panel for Primary Membranous Nephropathy (PMN) - (panel 584)
Anti-PLA2R and Anti-THSD7A Screening. For follow-up of positive results for PLA2R, an anti-PLA2R (ELISA) No. 247 is offered.

New panel for expanded analysis - suspected autoimmune hepatitis (panel 018)
Liver screen (anti-LKM-1, LC-1, AMA-M2, M2-3E (BPO). Sp100, PML, gp210, SLA / LP & Ro-52). Can only be ordered as a panel. This means that anti-SLA / LP is no longer included in panel 515.

New panel for expanded analysis - suspected autoantibodies in Autoimmune pancreatitis type 2 (AIP2), (panel 575).
Anti-Carboanhydrase II No. 850, anti-Lactoferrin (DNA bound) No. 859, anti-Thyreoglobulin No. 865 and IIF ANCA (p-ANCA).

New subclass determination of specific IgG for GBM (IgG1-4), no. 100 and GBM (IgG4), (no. 145).
An additional test for the GBM assay.

Panel no. 501; Suspected systemic vasculitis & anti-GBM disease. A test for ds-DNA has been added.

Panel 520 - connective tissue disease – undifferentiated
The IIF-ANCA test has been removed from the panel.

Panel 530 Sudden deafness
IIF-ANCA and anti-cardiolipin have been removed from the panel and PR3-ANCA has been added.

Panel 512 - when investigating for Celiac disease, test for anti-transglutaminase (IgA) and IgA quantification will primarily be performed
If IgA deficiency is detected, analysis for Transglutaminase IgG and Deamidated Gliadin IgG is further performed.

Panel 578 - when investigating for Celiac disease in children, an expanded analysis is offered - tests for anti-Endomysium IgA and Deamidated Gliadin IgA

Neurology

When testing for Gangliosides (GM1, GM2, Gd1a, Gd1b and Gq1b) - serum should always be used as sample material in the first place.

Monitoring of biological drugs (TDM; Therapeutic Drug Monitoring)

No TDM samples need to be sent frozen any longer. They should be sent at room temperature or cooled (between cold packs). This is clearly stated on the Request Forms for each drug.

REMOVED FROM THE PORTFOLIO:

Analysis no:
092 anti-skin IIF has been removed from the portfolio and thus also from panel no. 550.
008 IIF-ANCA is no longer included in panel 503 or 530 but remains in panels 541 and 575.

NEW NAME AND NEW WEB ADDRESS

On September 1, 2018, our parent company changed its name from Euro Diagnostica to Svar Life Science AB.

For Wieslab's part, this means that we have a new logotype, new address for our website www.svarlifescience.com, new email addresses (firstname.lastname@svarlifescience).

We are still in our premises in Malmö so there has been no change in terms of address or telephone numbers.

UPDATED REQUEST FORMS

Our Request Forms have been updated with the above changes and have new color coding: Autoimmune Diagnostics are clear blue (previously red), Neurology is gray (formerly light purple) and Monitoring of Biological Drugs is black (formerly dark blue). This means that the sample material that we receive will be analyzed according to the content of the updated Request Forms even if the sample material is sent together with an "old" Request Forms.

NEW PRICE LIST FOR 2019

Can be ordered via email to Diagnostic.services@svarlifescience.com
You can also contact Sr Key Account Manager, Monica Blixt: monica.blixt@svarlifescience.com

@INVOICING

In January 2019, we will implement @invoicing. This means that we will not send any paper invoices if you as customers do not specifically request it. For this to work as well as possible, it is important that you provide the correct reference code/cost center on the Request Forms.

FOR MORE INFORMATION, PLEASE CONTACT:

Diagnostic.services@svarlifescience.com
Lab Manager, Rita Martins Olofsson: 040 - 643 44 12,
Key Account Manager, Monica Blixt: 0708 - 86 28 10,
Laboratory: 040 - 53 76 60

Click on the links for more information on:
Sampling instructions
Request Forms
Opening hours
Terms & Conditions

21 January 2019

We’ve launched our new website and we’re excited to introduce you to our new look!

Svar Life Science is proud to announce the launch of our new website which coincides with us transitioning into a new brand and expanding our role as your partner for researching diagnostic strategies for personalized medicine and developing companion diagnostics based on assays customized for you. 

Our new website provides a clear message of who we are, what we stand for and and how we invent, develop and apply the best analytical technologies for drug development and clinical research, and establish practical platforms for routine diagnosis.

The website also boasts a clean Scandinavian design and consistent site-wide search system with improved menu functionality. It is also fully responsive with mobile devices, making it easy to navigate on a wide range of web browsers and portable devices.

We will continue to introduce a range of new content to the website and build a knowledge repository for to help you make the right decisions about partnering up with us, our laboratory services or purchasing our products. We also plan to continue adding more content about how we can help to push the boundaries in drug discovery and clinical diagnostics and provide you with all of the information you need to evaluate our products and services.

We’re really proud of the new website and feel it will create the experience you’re looking for when you pay us a visit. Svar means answers in Swedish. If you have questions, we can help you find the right answers. Contact us today.

21 November 2018

The Euro Diagnostica Group of Companies Announces Corporate Rebranding

The Euro Diagnostica group of companies, providers of analytical technologies for drug development, laboratory services, clinical research and practical platforms for routine diagnosis, today announced the launch of a new corporate name. The group will now be known as Svar Life Science. Among the other changes will be its logos and tagline.

The Euro Diagnostica group of companies today announced a corporate rebrand to Svar Life Science. The companies formerly known as Euro Diagnostica AB and Wieslab AB are now operational as “Svar Life Science AB” and “Wieslab AB, a Svar Life Science company”. The rebranding consists of: a new corporate brand structure, a new slogan, and a new focus for the group.

As a global supplier and partner within drug discovery and clinical diagnostics, the Svar Life Science group of companies have more than 30 years of experience serving the life science market with products and laboratory services aimed at helping customers move forward in the drug development process.

The group will continue to find and harness the optimal solutions through mergers, acquisitions, in-house innovation, industry collaboration and knowledge exchange and the adoption of a new brand signifies new beginnings.

In Swedish Svar means answers and the brand reflects the evolution of the company, the vision for the future as well as a strong Scandinavian heritage and the attributes associated with it: reliability, quality, expertise, responsiveness and focus on people.

With this corporate rebranding, the Svar Life Science group of companies are strengthening their focus of delivering a full suite of products and services to life science companies which is reflected in the new tagline, "Answers in Life Science."

Ron Long, CEO, Svar Life Science, said:

This rebrand represents a significant step in the company’s evolution and forms a part of our strategy of focusing our product portfolio and core technologies to deliver high quality solutions, the best analytical technologies and platforms for drug development, clinical research and routine diagnosis – answering to the needs in drug discovery and clinical diagnostics today.

About Svar Life Science

Svar Life Science is a Swedish life science company that invents, develops and applies the best analytical technologies for drug development and clinical research, and establishes practical platforms for routine diagnosis. You can be sure of our answers: we’ve been working right across the clinical diagnostic value chain for over 30 years.

Svar is your partner for researching diagnostic strategies for personalized medicine and developing companion diagnostics based on assays customized for you. Once the assays are established, you can use us for dedicated testing in early discovery, preclinical and clinical phases. Our special competence areas are autoimmune disease, inflammatory disease and cancer, with a focus on IBD and RA.

Contact:

Svar Life Science:

Jörgen Dahlström, Chief Business Officer
T     +46 40 53 76 08
E     Jorgen.Dahlstrom@svarlifescience.com

Wieslab AB, a Svar Life Science company
Michael Akoh, Vice President Laboratory Services
T     +46 40 53 76 31
E     Michael.Akoh@svarlifescience.com

26 October 2018

New Product Line - iLite® Assay Ready Cells for determination of ADCC activity

Svar Life Science AB today announced the availability of a new product line, the iLite® ADCC Activity Assay product line. The new iLite® ADCC Activity Assays enables measurement of Antibody-dependent cell-medicated cytotoxicity (ADCC) in a straight forward, sensitive and reproducible manner.

The new iLite® ADCC Activity Assay product line enables measurement of Antibody-dependent cell-medicated cytotoxicity (ADCC) in a straight forward, sensitive and reproducible manner. The new product line broadens Svar Life Sciences´ offering of cell-based assays and complement the product and service solutions already appreciated by pharmaceutical clients.

Jörgen Dahlström, Chief Business Officer, Svar Life Science, says:

"Antibody therapy has been proven to be highly powerful for cancer treatment and an important mechanism is the ability of antibody drugs to kill targeted tumour cells by Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). It is our aim to launch new and unique products within this field since the addition complements our existing assay solutions, and cements Svar Life Science position as a supplier of products and services for the pharma industry”.

Product details:

The iLite® ADCC Activity Set contains 3 different genetically modified cell lines; a reporter Effector cell, a positive Target cell and a negative Target cell. All three products can be supplied individually or in combination as iLite® ADCC Activity Set. These Activity sets enables measurements of an anti-targeted drug’s ability to induce ADCC, does not require any cell culturing and allow results to be read within 4 hours. In addition, the Effector cells, which can be used with any Target cell, include a normalization readout which can be used to adjust for differences in cell counts.

Target cells for HER2. EGFR and membrane bound TNF- alpha will be the first to be launched, followed by shortly by CD20 Target cells.

The unique set-up of Assay Ready effector cells and matched target cells, engineered to work optimally together, gives unparalleled sensitivity and with the launch of the first products in the iLite® ADCC product line, we can successfully assist clients with accelerating their drug discovery and development programs” adds Therese Segerstein, Product Manager Cell Based Assays.

As all iLite® cell lines, the ADCC products are provided as Assay Ready Cells and can be set up and performed through our bioanalytical service laboratory in compliance with GLP and GCP.

For further information please contact:

Therese Segerstein
Product Manager Cell Based Assays
T +46 40 643 49 21
E therese.segerstein@svarlifescience.com

Camilla Duborn
Senior Director Sales EMEA & APAC
T +46 40 53 76 11
E camilla.duborn@svarlifescience.com

25 October 2018

Are you looking for a highly specific C4d assay?

Check out our newest addition to the Svar Life Science Complement range – the Complement C4d Assay!

Svar Life Science, is excited to launch a C4d Assay Kit. C4d can be used as a complement activity marker for the classical and lectin pathways and the assay is targeting a unique cleavage epitope on C4d, which means that only the C4d is measured.

The complement system plays an essential role in autoimmune and infectious diseases. There are three pathways of complement activation; the classical, the alternative and the lectin pathway.

The C4d protein is a product of the classical and the lectin pathways and now Svar Life Science has developed a C4d Elisa kit to measure C4d in human plasma.

The Svar Life Science complement C4d assay is a highly specific complement activity marker for the classical and lectin pathway.

The Svar C4d assay:

  • Only measures C4d – does not cross react with C4 or other related complement proteins
  • Detect both variants of C4d
  • Targeted to the C4d unique cleavage epitope
  • User friendly format - ready to use reagents & short incubation times

For a detailed description of this product please click here.

25 October 2018